National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, GA, USA.
Centre de recherche du CHU de Québec - Université Laval, Axe santé des populations et pratiques optimales en santé, Québec, Canada.
Vaccine. 2022 Sep 2;40(37):5413-5432. doi: 10.1016/j.vaccine.2022.06.065. Epub 2022 Aug 12.
Human papillomavirus (HPV) vaccines were first licensed as a three-dose series. Two doses are now widely recommended in some age groups; there are data suggesting high efficacy with one dose. We updated a systematic literature review of HPV vaccine effectiveness by number of doses in observational studies.
We searched Medline and Embase databases from January 1, 2007, through September 29, 2021. Data were extracted and summarized in a narrative synthesis. We also conducted quality assessments for bias due to selection, information, and confounding.
Overall, 35 studies were included; all except one were conducted within the context of a recommended three-dose schedule. Evaluations were in countries that used bivalent HPV vaccine (seven), quadrivalent HPV vaccine (27) or both (one). Nine evaluated effectiveness against HPV infection, ten anogenital warts, and 16 cervical abnormalities. All studies were judged to have moderate or serious risk of bias. The biases rated as serious would likely result in lower effectiveness with fewer doses. Investigators attempted to control for or stratify by potentially important variables, such as age at vaccination. Eight studies evaluated impact of buffer periods (lag time) for case counting and 10 evaluated different intervals between doses for two-dose vaccine recipients. Studies that stratified by vaccination age found higher effectiveness with younger age at vaccination, although differences were not all formally tested. Most studies found highest estimates of effectiveness with three doses; significant effectiveness was found among 28/29 studies that evaluated three doses, 19/29 that evaluated two doses, and 18/30 that evaluated one dose. Some studies that adjusted or stratified analyses by age at vaccination found similar effectiveness with three, two and one doses.
Observational studies of HPV vaccine effectiveness have many biases. Studies examining persons vaccinated prior to sexual activity and using methods to reduce sources of bias are needed for valid effectiveness estimates.
人乳头瘤病毒(HPV)疫苗最初被批准为三剂系列。现在,在某些年龄组中广泛推荐两剂;有数据表明一剂也有很高的疗效。我们更新了一项关于观察性研究中 HPV 疫苗有效性的系统文献综述,按剂量数进行分析。
我们从 2007 年 1 月 1 日至 2021 年 9 月 29 日,在 Medline 和 Embase 数据库中进行了搜索。提取数据并进行了叙述性综合总结。我们还对由于选择、信息和混杂因素引起的偏倚进行了质量评估。
共纳入 35 项研究;除一项外,其余均在推荐的三剂方案背景下进行。评估在使用二价 HPV 疫苗(7 项)、四价 HPV 疫苗(27 项)或两者(1 项)的国家进行。9 项评估了针对 HPV 感染的有效性,10 项评估了肛门生殖器疣,16 项评估了宫颈异常。所有研究均被判定为存在中度或严重的偏倚风险。被评为严重偏倚的偏差可能会导致剂量减少而降低有效性。研究人员试图控制或分层潜在重要变量,如接种年龄。8 项研究评估了病例计数的缓冲期(滞后时间)的影响,10 项研究评估了两剂疫苗接种者之间不同的剂量间隔。按接种年龄分层的研究发现,接种年龄越小,有效性越高,尽管并非所有差异都经过了正式检验。大多数研究发现三剂疫苗的有效性最高;在 29 项评估三剂疫苗的研究中,28 项发现了显著的有效性,29 项评估两剂疫苗的研究中有 19 项发现了有效性,30 项评估一剂疫苗的研究中有 18 项发现了有效性。一些按接种年龄调整或分层分析的研究发现,三剂、两剂和一剂的有效性相似。
HPV 疫苗有效性的观察性研究存在许多偏倚。需要对在性行为前接种疫苗并使用减少偏倚来源的方法的人群进行研究,以获得有效的有效性估计。